Plexium Inc. has described compounds acting as probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) degradation inducers reported to be useful for the treatment of cancer.